menu
    • menu
    [{"orgOrder":0,"company":"Nucleus RadioPharma","sponsor":"Eclipse","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Financing","leadProduct":"Radiopharmaceutical Therapy","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Nucleus RadioPharma","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"Nucleus RadioPharma \/ Eclipse","highestDevelopmentStatusID":"1","companyTruncated":"Nucleus RadioPharma \/ Eclipse"},{"orgOrder":0,"company":"Nucleus RadioPharma","sponsor":"NorthStar Medical Radioisotopes","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Actinium-225 Conjugated Therapy","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Nucleus RadioPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Nucleus RadioPharma \/ Nucleus RadioPharma","highestDevelopmentStatusID":"4","companyTruncated":"Nucleus RadioPharma \/ Nucleus RadioPharma"},{"orgOrder":0,"company":"Nucleus RadioPharma","sponsor":"ARTBIO","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2024","type":"Collaboration","leadProduct":"212Pb-NG001","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nucleus RadioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Nucleus RadioPharma \/ ARTBIO","highestDevelopmentStatusID":"6","companyTruncated":"Nucleus RadioPharma \/ ARTBIO"}]

    Find Clinical Drug Pipeline Developments & Deals by Nucleus RadioPharma

    Menu

    Nucleus RadioPharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Nucleus RadioPharma

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Nucleus RadioPharma

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 212Pb-NG001

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : ARTBIO

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            ARTBIOS and Nucleus RadioPharma Collaborate for GMP-Grade Therapeutics with Pb-212

                            Details : Under the agreement, Nucleus will manufacture ARTBIO's 212Pb-radiolabeled therapies for Phase I and II trials in prostate cancer, using ARTBIO’s AlphaDirect™ 212Pb isolation technology.

                            Brand Name : AB001

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            May 07, 2024

                            Lead Product(s) : 212Pb-NG001

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : ARTBIO

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Nucleus RadioPharma

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Nucleus RadioPharma

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Actinium-225 Conjugated Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : NorthStar Medical Radioisotopes

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            NorthStar Medical Radioisotopes Announces Supply Agreement with Nucleus RadioPharma for Alpha-Emitting Therape...

                            Details : Under terms of the agreement, NorthStar will supply its high purity, non-carrier added Ac-225 to Nucleus. Nucleus will use NorthStar’s Ac-225 for their customers’ Actinium-225 conjugated therapy programs.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            June 27, 2023

                            Lead Product(s) : Actinium-225 Conjugated Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : NorthStar Medical Radioisotopes

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Nucleus RadioPharma

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Nucleus RadioPharma

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Radiopharmaceutical Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Eclipse

                            Deal Size : $6.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Eclipse and Mayo Clinic Create Nucleus RadioPharma to Better Serve Cancer Patients

                            Details : The organization draws on Eclipse's experience creating companies with advanced manufacturing technologies, as well as the deep oncology expertise of Mayo Clinic, one of the largest nuclear medicine practices in the world.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 12, 2022

                            Lead Product(s) : Radiopharmaceutical Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Eclipse

                            Deal Size : $6.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth